Results 121 to 130 of about 7,577 (154)

The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy. [PDF]

BMC Cancer
Wang YL, Chang TY, Chen SH, Hsiao YW, Wen YC, Jaing TH.   +5 more
europepmc   +1 more source

Navigating Cardiotoxicity in Cancer Treatment: Insights into Fluoropyrimidine-induced Cardiac Events. [PDF]

Curr Cardiol Rev
Bhattarai A, Chakraborty M, Ali MHJ, Sharma C, Rai A, Acharya R, Rai Y, Bhattacharjee A, Bhuyan NR.   +8 more
europepmc   +1 more source

Influence of xanthine oxidase and inosine monophosphate dehydrogenase polymorphisms on 6-mercaptopurine treatment response in pediatric acute lymphoblastic leukemia. [PDF]

Sci Rep
Sabirova Z, Boucetta MTE, Bensouyad RR, Gagné V, Théorêt Y, Nava T, Leclerc JM, Laverdière C, Sinnett D, Tran TH, Krajinovic M.   +10 more
europepmc   +1 more source

Synthesis and use of polyamine derivatives as internal mass spectrometry standards [PDF]

Dar, Sami Ullah
core  

Some of the next articles are maybe not open access.

Related searches:

The efficacy and toxicity of antineoplastic antimetabolites: Role of gut microbiota

Toxicology, 2021
The incidence and mortality of cancer are rapidly growing all over the world. Nowadays, antineoplastic antimetabolites still play a key role in the chemotherapy of cancer. However, the interindividual variations in the efficacy and toxicity of antineoplastic antimetabolites are nonnegligible challenges to their clinical applications.
Xinyi Huang, Lulu Chen, Zhenyu Li, Binjie Zheng, Na Liu, Qing Fang, Jinsheng Jiang, Tai Rao, Dongsheng Ouyang   +8 more
openaire   +2 more sources

Nelarabine: A novel purine antimetabolite antineoplastic agent

Clinical Therapeutics, 2007
Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.This article reviews the pharmacology, mechanism of action, and ...
Larry W, Buie, Stacy S, Epstein, Celeste M, Lindley   +2 more
openaire   +2 more sources

Intercalator-induced, toposiomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites

International Journal of Radiation Oncology*Biology*Physics, 1986
Defining specific biochemical targets of active antineoplastic agents could aid in discovering better anticancer therapy and more thoroughly understanding the biochemical basis of malignancy. Through a series of cellular and biochemical studies, we and others have identified the nuclear enzyme topoisomerase II as the target of several active agents ...
L A, Zwelling, L, Silberman, E, Estey
openaire   +2 more sources

Glycolysis-dependent antimetabolites: Possible improvement in antineoplastic selectivity

Medical Hypotheses, 1979
The increased rate of glycolysis in neoplastic cells may be used to design tentatively antimetabolites whose detoxification would be faster in normal cells. Pyruvo-substituted nucleotides are examined in this respect and their expected differential metabolism outlined.
openaire   +2 more sources

Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays

Cancer Chemotherapy and Pharmacology, 1989
The stability of solutions of the antitumour antimetabolites, vinca alkaloids, podophyllotoxins, interferons, steroids and platinum drugs as well as maytansine, asparaginase, amsacrine, flavone-8-acetic acid, mitoguazone, and N-phosphonoacetyl-L-aspartate (PALA) is reviewed.
openaire   +2 more sources